IL302678A - History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer - Google Patents

History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer

Info

Publication number
IL302678A
IL302678A IL302678A IL30267823A IL302678A IL 302678 A IL302678 A IL 302678A IL 302678 A IL302678 A IL 302678A IL 30267823 A IL30267823 A IL 30267823A IL 302678 A IL302678 A IL 302678A
Authority
IL
Israel
Prior art keywords
12alkyl
independently
compound
pharmaceutically acceptable
foregoing
Prior art date
Application number
IL302678A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL302678A publication Critical patent/IL302678A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL302678A 2020-11-11 2020-11-30 History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer IL302678A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112609P 2020-11-11 2020-11-11
PCT/US2020/062627 WO2022103411A1 (en) 2020-11-11 2020-11-30 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer

Publications (1)

Publication Number Publication Date
IL302678A true IL302678A (en) 2023-07-01

Family

ID=73839136

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302678A IL302678A (en) 2020-11-11 2020-11-30 History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer

Country Status (10)

Country Link
US (1) US20230391766A1 (https=)
EP (1) EP4244218A1 (https=)
JP (2) JP7654075B2 (https=)
KR (1) KR20230106637A (https=)
CN (1) CN116783183B (https=)
AU (1) AU2020476996A1 (https=)
CA (1) CA3197092A1 (https=)
IL (1) IL302678A (https=)
MX (1) MX2023005305A (https=)
WO (1) WO2022103411A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119677735A (zh) * 2022-05-11 2025-03-21 基因泰克公司 作为vhl配体的苯并噻唑化合物
WO2025162250A1 (zh) * 2024-02-04 2025-08-07 贝达药业股份有限公司 取代的三环化合物及其用途
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
WO2026012475A1 (en) * 2024-07-12 2026-01-15 Ascentage Pharma (Suzhou) Co., Ltd. Vhl ligands and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN110573507B (zh) * 2017-04-14 2023-11-14 邓迪大学 小分子
US11547759B2 (en) * 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Also Published As

Publication number Publication date
MX2023005305A (es) 2023-05-25
WO2022103411A1 (en) 2022-05-19
US20230391766A1 (en) 2023-12-07
KR20230106637A (ko) 2023-07-13
AU2020476996A1 (en) 2023-06-29
CN116783183A (zh) 2023-09-19
CA3197092A1 (en) 2022-05-19
CN116783183B (zh) 2026-03-20
JP7654075B2 (ja) 2025-03-31
JP2023549187A (ja) 2023-11-22
EP4244218A1 (en) 2023-09-20
JP2025063287A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
IL302678A (en) History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer
KR101686685B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
US9573943B2 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN107849055B (zh) 用作irak1/4抑制剂的大环化合物及其用途
IL272016B2 (en) Pyrrolidine derivatives and their use as tlr7/8 antagonists
IL258081B2 (en) Benzimidazole history and their use
KR20130086520A (ko) 스피로시클릭 화합물 및 이들의 치료제 및 진단 프로브로서 용도
AU2017348826A1 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CN107428765A (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途
CN108137559A (zh) 用作btk抑制剂的嘧啶衍生物及其用途
WO2024152710A1 (zh) 谷氨酰胺环化酶抑制剂及其应用
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
IL302677A (en) History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia
US20250129063A1 (en) Benzothiazole compounds as vhl ligands
CA3256395A1 (fr) Procédé de test d'audiométrie vocale mettant en oeuvre une reconnaissance vocale et dispositif électronique associé
JP2019510054A (ja) シクロフィリンの阻害のための化合物及びその使用
TW202508585A (zh) 用於治療紫質症（ｐｏｒｐｈｙｒｉａ）之醯胺吡啶并［３，４－Ｂ］吲哚－１，４－二酮化合物
CN121226368A (zh) Ripk1抑制剂及其医药用途
HK40092810A (zh) 作为vhl抑制剂用於治疗贫血和癌症的1-(2-(4-环丙基-1h-1，2，3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
WO2026037254A1 (zh) 作为mrgprx2拮抗剂的化合物